1SXP logo

SCHOTT Pharma AG & Co. KGaA Stock Price

XTRA:1SXP Community·€3.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

1SXP Share Price Performance

€20.40
-9.26 (-31.22%)
43.3% undervalued intrinsic discount
€36.00
Fair Value
€20.40
-9.26 (-31.22%)
43.3% undervalued intrinsic discount
€36.00
Fair Value
Price €20.40
AnalystHighTarget €36.00
AnalystConsensusTarget €29.79
AnalystLowTarget €23.00

1SXP Community Narratives

AnalystHighTarget·
Fair Value €36 42.9% undervalued intrinsic discount

Aging Population And Biologics Growth Will Fuel Advanced Packaging

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value €29.33 29.9% undervalued intrinsic discount

Advanced Drug Delivery And Capacity Investments Will Shape Future Success

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystLowTarget·
Fair Value €22 6.6% undervalued intrinsic discount

Intensifying Climate Mandates And Protectionism Will Erode Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent 1SXP News & Updates

Investor Optimism Abounds SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) But Growth Is Lacking

Sep 19
Investor Optimism Abounds SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) But Growth Is Lacking

Analysts Are Updating Their SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Estimates After Its Third-Quarter Results

Aug 15
Analysts Are Updating Their SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Estimates After Its Third-Quarter Results

These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well

Jul 19
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well

Does SCHOTT Pharma KGaA (ETR:1SXP) Deserve A Spot On Your Watchlist?

Jun 13
Does SCHOTT Pharma KGaA (ETR:1SXP) Deserve A Spot On Your Watchlist?

Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

May 18
Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

An Intrinsic Calculation For SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Suggests It's 40% Undervalued

Apr 27
An Intrinsic Calculation For SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Suggests It's 40% Undervalued

SCHOTT Pharma AG & Co. KGaA Key Details

€975.7m

Revenue

€646.6m

Cost of Revenue

€329.1m

Gross Profit

€182.2m

Other Expenses

€146.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Dec 11, 2025
Earnings per share (EPS)
0.98
Gross Margin
33.73%
Net Profit Margin
15.05%
Debt/Equity Ratio
24.0%

SCHOTT Pharma AG & Co. KGaA Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and fair value.

0 Risks
3 Rewards

About 1SXP

Founded
1884
Employees
4775
CEO
Andreas Reisse
WebsiteView website
www.schott-pharma.com

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. It offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. The company also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products comprise Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

German Market Performance

  • 7 Days: -1.0%
  • 3 Months: -1.6%
  • 1 Year: 12.4%
  • Year to Date: 12.1%
Over the last 7 days, the market has dropped 1.0%, driven by pullbacks in the Consumer Discretionary and Industrials sectors of 4.0% and 1.8%, respectively. In contrast to the last week, the market is actually up 12% over the past year. Earnings are forecast to grow by 17% annually. Market details ›